Abstract
Binge eating behavior has been noted in some eating disorders as well as in obesity. The goal of this paper is to review current, non-serotonergic pharmaceutical approaches to treat binge eating. Further, using information derived from preclinical models, we discuss candidate neurotransmitter systems for study as targets for the treatment of binge eating. Dopaminergic circuits have been implicated in both laboratory animal models and human studies of binge eating, though existing medications specifically targeting the dopaminergic system have been found to have adverse side effects. Opioidergic and gamma-aminobutyric acid (GABA) systems also appear to be highly involved in aspects of binge eating; further, opioid antagonists, such as naltrexone, and GABA agonists, such as baclofen, have all been shown to be effective in treating alcohol dependence and may be equally efficacious in attenuating binge eating. Preclinical evidence, and some clinical evidence, suggests that cannabinoid antagonism may also be useful in the treatment of binge eating, although the specific effect of antagonists on binge consumption remains unclear. Overall, each of these neurotransmitter systems provides a promising avenue for new pharmacotherapy development for binge eating, and preclinical and human studies provide a strong rationale for the development of highly-selective drugs that target this neurocircuitry.
Keywords: Binge eating, preclinical models, dopamine, opioid, cannabinoid, GABA
Current Pharmaceutical Design
Title: Pharmacological Interventions for Binge Eating: Lessons from Animal Models, Current Treatments, and Future Directions
Volume: 17 Issue: 12
Author(s): Laura A. Berner, Miriam E. Bocarsly, Bartley G. Hoebel and Nicole M. Avena
Affiliation:
Keywords: Binge eating, preclinical models, dopamine, opioid, cannabinoid, GABA
Abstract: Binge eating behavior has been noted in some eating disorders as well as in obesity. The goal of this paper is to review current, non-serotonergic pharmaceutical approaches to treat binge eating. Further, using information derived from preclinical models, we discuss candidate neurotransmitter systems for study as targets for the treatment of binge eating. Dopaminergic circuits have been implicated in both laboratory animal models and human studies of binge eating, though existing medications specifically targeting the dopaminergic system have been found to have adverse side effects. Opioidergic and gamma-aminobutyric acid (GABA) systems also appear to be highly involved in aspects of binge eating; further, opioid antagonists, such as naltrexone, and GABA agonists, such as baclofen, have all been shown to be effective in treating alcohol dependence and may be equally efficacious in attenuating binge eating. Preclinical evidence, and some clinical evidence, suggests that cannabinoid antagonism may also be useful in the treatment of binge eating, although the specific effect of antagonists on binge consumption remains unclear. Overall, each of these neurotransmitter systems provides a promising avenue for new pharmacotherapy development for binge eating, and preclinical and human studies provide a strong rationale for the development of highly-selective drugs that target this neurocircuitry.
Export Options
About this article
Cite this article as:
A. Berner Laura, E. Bocarsly Miriam, G. Hoebel Bartley and M. Avena Nicole, Pharmacological Interventions for Binge Eating: Lessons from Animal Models, Current Treatments, and Future Directions, Current Pharmaceutical Design 2011; 17 (12) . https://dx.doi.org/10.2174/138161211795656774
DOI https://dx.doi.org/10.2174/138161211795656774 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab) in the Therapy of Moderate-to-Severe Allergic Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Present Drug Therapy of Demyelinating Disorders
Current Drug Therapy Evaluation of the Fibromyalgia and Related Risk Factors in Patients with Advanced Kidney Failure Undergoing Hemodialysis
Current Rheumatology Reviews Chinese Herbal Medicine for Hyperlipidaemia: A Review Based on Data Mining from 1990 to 2016
Current Vascular Pharmacology Beneficial and Adverse Effects of Molecularly Targeted Therapies for Acute Promyelocytic Leukemia in Central Nervous System
CNS & Neurological Disorders - Drug Targets Do we Need a New Procedure for the Assessment of Adverse Events in Anti-migraine Clinical Trials?
Recent Patents on CNS Drug Discovery (Discontinued) Pleiotropic Effects of Cardioactive Glycosides
Current Medicinal Chemistry Update on the Use of Biologics in Vasculitides
Current Pharmaceutical Biotechnology From Nature to Drug Discovery: The Indole Scaffold as a ‘Privileged Structure’
Mini-Reviews in Medicinal Chemistry Do Substance P and the NK1 Receptor have a Role in Depression and Anxiety?
Current Pharmaceutical Design Adjuvant Therapies of COVID-19 - A Literature Review
Coronaviruses Nocturia in Obstructive Sleep Apnea-Hypopnea Syndrome: An Underappreciated Symptom
Current Respiratory Medicine Reviews Oxycodone/Naloxone in the Management of Patients with Pain and Opioid–Induced Bowel Dysfunction
Current Drug Targets New Antihypertensive Drugs Under Development
Current Medicinal Chemistry Novel and Emerging Drugs for Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Coenzyme Q10 and Neurological Diseases: An Update
Letters in Drug Design & Discovery Review of Medicinal Plants Common to Traditional Chinese and Indian Medicines with Relevance to Non-Communicable Diseases
Current Traditional Medicine Probenecid: An Emerging Tool for Neuroprotection
CNS & Neurological Disorders - Drug Targets Long-Term Safety from the Raltegravir Clinical Development Program
Current HIV Research Mixed Connective Tissue Disease (MCTD) – A Coming of Age
Current Rheumatology Reviews